A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC--Total In Cystic Fibrosis Subjects with Exocrine Pancreatic Insufficiency

Grants and Contracts Details

StatusFinished
Effective start/end date6/1/048/31/05

Funding

  • Altus Pharmaceuticals Inc.: $52,541.00